- Home
- CC vs GERN Comparison
CC vs GERN Comparison
Compare CC & GERN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CC
- GERN
- Stock Information
- Founded
- CC 2014
- GERN 1990
- Country
- CC United States
- GERN United States
- Employees
- CC N/A
- GERN N/A
- Industry
- CC Major Chemicals
- GERN Biotechnology: Pharmaceutical Preparations
- Sector
- CC Industrials
- GERN Health Care
- Exchange
- CC Nasdaq
- GERN Nasdaq
- Market Cap
- CC 2.9B
- GERN 2.5B
- IPO Year
- CC N/A
- GERN 1996
- Fundamental
- Price
- CC $18.24
- GERN $3.87
- Analyst Decision
- CC Buy
- GERN Strong Buy
- Analyst Count
- CC 8
- GERN 10
- Target Price
- CC $24.88
- GERN $7.05
- AVG Volume (30 Days)
- CC 1.7M
- GERN 6.7M
- Earning Date
- CC 11-04-2024
- GERN 11-07-2024
- Dividend Yield
- CC 5.51%
- GERN N/A
- EPS Growth
- CC N/A
- GERN N/A
- EPS
- CC 0.50
- GERN N/A
- Revenue
- CC $5,749,000,000.00
- GERN $29,480,000.00
- Revenue This Year
- CC N/A
- GERN $32,021.10
- Revenue Next Year
- CC $5.08
- GERN $298.14
- P/E Ratio
- CC $36.20
- GERN N/A
- Revenue Growth
- CC N/A
- GERN 9199.68
- 52 Week Low
- CC $15.10
- GERN $1.64
- 52 Week High
- CC $32.70
- GERN $5.34
- Technical
- Relative Strength Index (RSI)
- CC 34.27
- GERN 46.32
- Support Level
- CC $18.13
- GERN $3.75
- Resistance Level
- CC $22.27
- GERN $4.00
- Average True Range (ATR)
- CC 0.81
- GERN 0.15
- MACD
- CC -0.41
- GERN -0.00
- Stochastic Oscillator
- CC 4.11
- GERN 40.00
About CC Chemours Company (The)
The Chemours Co is a global provider of chemicals. It delivers customized solutions with a wide range of industrial and specialty chemicals products for various markets including coatings, plastics, refrigeration, air conditioning, etc. The company's operating segments include Titanium Technologies, Thermal & Specialized Solutions, and Advanced Performance Materials. It generates maximum revenue from the Titanium Technologies segment. The Titanium Technologies segment is a producer of TiO2 pigment, a premium white pigment used to deliver whiteness, brightness, opacity, durability, efficiency, and protection across a variety of applications. Geographically, the company derives a majority of its revenue from North America.
About GERN Geron Corporation
Geron Corp is a clinical-stage biopharmaceutical company focused on the research and development of cancer treatments. The company's drug in development, Imelstat, is being tested for the treatment of myelodysplastic syndromes, which are disorders of the blood, and myelofibrosis, which is a rare blood cancer affecting bone marrow. The company earns revenue through collaboration agreements, milestones, royalties, and licensing arrangements. Geron possesses various rights to this drug. The company operates as a single segment being, the development of therapeutic products for oncology.